Stay updated on Pembrolizumab with BCG in HR NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab with BCG in HR NMIBC Clinical Trial page
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedAdded registry identifiers U1111-1282-1555 and 2022-501817-29-00. Replaced old EngageZone data-sharing references with trialstransparency.msdclinicaltrials.com and externaldatasharing-msd.com.SummaryDifference0.2%

- Check23 days agoChange DetectedThe Locations section now includes a large expansion of study sites across multiple countries and regions, listing new sites in the US, Canada, Europe, Asia, Australia, and South America. Several previously listed sites have been removed.SummaryDifference4%

- Check45 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; this maintenance update does not affect the study details, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedEditorial updates to the Publications section clarify that items are auto-filled from PubMed and may not all pertain to the study; revision tag updated from v3.2.0 to v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange DetectedThe government funding status notice on the page has been removed.SummaryDifference0.1%

- Check73 days agoChange DetectedTwo location entries in the Locations list were renamed from 'Santiago de Cali' to 'Cali' for postal codes 76001 and 760042 in Valle del Cauca, Colombia.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab with BCG in HR NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with BCG in HR NMIBC Clinical Trial page.